When the Minimal Becomes Measurable

Cancer Genome Atlas Research Network, None, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia The New England Journal of Medicine. ,vol. 368, pp. 2059- 2074 ,(2013) , 10.1056/NEJMOA1301689

Peter Hokland, Hans B. Ommen, Matthew P. Mulé, Christopher S. Hourigan, Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia Seminars in Hematology. ,vol. 52, pp. 184- 192 ,(2015) , 10.1053/J.SEMINHEMATOL.2015.04.001

PhD Jeffery M. Klco, MD, PhD Christopher A. Miller, PhD Malachi Griffith, PhD Allegra Petti, PhD David H. Spencer, MD, MS Shamika Ketkar-Kulkarni, MD Lukas D. Wartman, PhD Matthew Christopher, MD, BS Tamara L. Lamprecht, BS Nicole M. Helton, MD Eric J. Duncavage, PhD Jacqueline E. Payton, MD, BA Jack Baty, Sharon E. Heath, PhD Obi L. Griffith, PhD Dong Shen, MS Jasreet Hundal, PhD Gue Su Chang, MS Robert Fulton, BS Michelle O'Laughlin, BS Catrina Fronick, PhD Vincent Magrini, BE Ryan T. Demeter, PhD David E. Larson, PhD Shashikant Kulkarni, MS, PhD Bradley A. Ozenberger, PhD John S. Welch, MD, MD Matthew J. Walter, MD Timothy A. Graubert, PhD Peter Westervelt, MD, MD Jerald P. Radich, MD Daniel C. Link, PhD Elaine R. Mardis, PhD John F. DiPersio, MD, PhD Richard K. Wilson, MD Timothy J. Ley, Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia JAMA. ,vol. 314, pp. 811- 822 ,(2015) , 10.1001/JAMA.2015.9643

Christopher S. Hourigan, Judith E. Karp, Minimal residual disease in acute myeloid leukaemia. Nature Reviews Clinical Oncology. ,vol. 10, pp. 460- 471 ,(2013) , 10.1038/NRCLINONC.2013.100

Sabine Kayser, Richard F. Schlenk, David Grimwade, Victor E. D. Yosuico, Roland B. Walter, Minimal residual disease-directed therapy in acute myeloid leukemia. Blood. ,vol. 125, pp. 2331- 2335 ,(2015) , 10.1182/BLOOD-2014-11-578815

M Goswami, K S McGowan, K Lu, N Jain, J Candia, N F Hensel, J Tang, K R Calvo, M Battiwalla, A J Barrett, C S Hourigan, A multigene array for measurable residual disease detection in AML patients undergoing SCT Bone Marrow Transplantation. ,vol. 50, pp. 642- 651 ,(2015) , 10.1038/BMT.2014.326

Daniela Cilloni, Aline Renneville, Fabienne Hermitte, Robert K. Hills, Sarah Daly, Jelena V. Jovanovic, Enrico Gottardi, Milena Fava, Susanne Schnittger, Tamara Weiss, Barbara Izzo, Josep Nomdedeu, Adrian van der Heijden, Bert A. van der Reijden, Joop H. Jansen, Vincent H.J. van der Velden, Hans Ommen, Claude Preudhomme, Giuseppe Saglio, David Grimwade, Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study Journal of Clinical Oncology. ,vol. 27, pp. 5195- 5201 ,(2009) , 10.1200/JCO.2009.22.4865

David Grimwade, Jelena V. Jovanovic, Robert K. Hills, Elizabeth A. Nugent, Yashma Patel, Rajinder Flora, Daniela Diverio, Katy Jones, Hannah Aslett, Elaine Batson, Kristian Rennie, Roger Angell, Richard E. Clark, Ellen Solomon, Francesco Lo-Coco, Keith Wheatley, Alan K. Burnett, Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy Journal of Clinical Oncology. ,vol. 27, pp. 3650- 3658 ,(2009) , 10.1200/JCO.2008.20.1533

Daisuke Araki, Brent L. Wood, Megan Othus, Jerald P. Radich, Anna B. Halpern, Yi Zhou, Marco Mielcarek, Elihu H. Estey, Frederick R. Appelbaum, Roland B. Walter, Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission? Journal of Clinical Oncology. ,vol. 34, pp. 329- 336 ,(2016) , 10.1200/JCO.2015.63.3826

Adam Ivey, Robert K. Hills, Michael A. Simpson, Jelena V. Jovanovic, Amanda Gilkes, Angela Grech, Yashma Patel, Neesa Bhudia, Hassan Farah, Joanne Mason, Kerry Wall, Susanna Akiki, Michael Griffiths, Ellen Solomon, Frank McCaughan, David C. Linch, Rosemary E. Gale, Paresh Vyas, Sylvie D. Freeman, Nigel Russell, Alan K. Burnett, David Grimwade, Assessment of Minimal Residual Disease in Standard-Risk AML. The New England Journal of Medicine. ,vol. 374, pp. 422- 433 ,(2016) , 10.1056/NEJMOA1507471